Cardiac Magnetic Resonance and Cardio-Oncology: Does T Signal the End of Anthracycline Cardiotoxicity?
作者信息
Yu Anthony F, Chan Angel T, Steingart Richard M
机构信息
Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
出版信息
J Am Coll Cardiol. 2019 Feb 26;73(7):792-794. doi: 10.1016/j.jacc.2018.11.045.
Abstract
摘要
相似文献
1
Cardiac Magnetic Resonance and Cardio-Oncology: Does T Signal the End of Anthracycline Cardiotoxicity?心脏磁共振与心脏肿瘤学：T 是否预示着蒽环类药物心脏毒性的终结？
J Am Coll Cardiol. 2019 Feb 26;73(7):792-794. doi: 10.1016/j.jacc.2018.11.045.
2
Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.基于磁共振成像的连续监测用于诊断蒽环类药物诱导的心脏毒性的早期阶段。
J Am Coll Cardiol. 2019 Feb 26;73(7):779-791. doi: 10.1016/j.jacc.2018.11.046.
3
Coronary microcirculation damage in anthracycline cardiotoxicity.蒽环类药物心脏毒性中的冠状动脉微循环损伤
Cardiovasc Res. 2022 Jan 29;118(2):531-541. doi: 10.1093/cvr/cvab053.
4
Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes.超高场心血管磁共振 T1 和 T2 mapping 用于评估大鼠模型中蒽环类药物诱导的心脏毒性：与组织病理学变化的对比验证。
J Cardiovasc Magn Reson. 2021 Jun 17;23(1):76. doi: 10.1186/s12968-021-00767-8.
5
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.他汀类药物预防接受蒽环类药物治疗的高心脏毒性风险的癌症患者早期心脏功能障碍。
Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):515-525. doi: 10.1093/ehjcvp/pvad031.
6
Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.心脏磁共振特征追踪技术评价蒽环类药物治疗的非霍奇金淋巴瘤成年幸存者亚临床舒张功能障碍。
BMC Cardiovasc Disord. 2021 Apr 12;21(1):170. doi: 10.1186/s12872-021-01996-6.
7
Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis.评估原发性心肌 T1 mapping 对癌症患者蒽环类药物诱导性心脏毒性的早期检测：系统评价和荟萃分析。
Cardiovasc Toxicol. 2024 Jun;24(6):563-575. doi: 10.1007/s12012-024-09866-1. Epub 2024 May 3.
8
Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity.远程缺血预处理可减轻蒽环类药物诱导的心脏毒性并维持线粒体完整性。
Cardiovasc Res. 2021 Mar 21;117(4):1132-1143. doi: 10.1093/cvr/cvaa181.
9
Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance.采用T2加权心脏磁共振成像对乳腺癌幸存者蒽环类药物所致心脏毒性进行早期检测
Circ Cardiovasc Imaging. 2019 May;12(5):e008777. doi: 10.1161/CIRCIMAGING.118.008777.
10
Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.现代蒽环类药物剂量对左心室射血分数的心脏毒性作用：来自随机对照试验安慰剂臂的系统评价和荟萃分析。
J Am Heart Assoc. 2021 Mar 16;10(6):e018802. doi: 10.1161/JAHA.120.018802. Epub 2021 Mar 4.
引用本文的文献
1
Effect of Catechin on Hepatotoxicity Induced by Combined Doxorubicin and Paclitaxel Treatment.儿茶素对多柔比星与紫杉醇联合治疗所致肝毒性的影响。
J Toxicol. 2025 Sep 3;2025:6775839. doi: 10.1155/jt/6775839. eCollection 2025.
2
Exploring the synergistic effects of metformin and doxorubicin loaded chitosan nanoparticles for A549 lung cancer therapy.探索负载二甲双胍和阿霉素的壳聚糖纳米颗粒对A549肺癌治疗的协同作用。
Sci Rep. 2025 Jul 2;15(1):22657. doi: 10.1038/s41598-025-07996-2.
3
Multifaced Anticancer Potential of Doxorubicin: Spotlight on Breast Cancer.多柔比星的多面抗癌潜力：聚焦乳腺癌
Dis Res. 2025 Mar;5(1):19-36. doi: 10.54457/dr.202402015. Epub 2025 Jan 17.
4
Doxorubicin as a Drug Repurposing for Disruption of α-Chymotrypsinogen-A Aggregates.多柔比星作为一种药物再利用，用于破坏α-糜蛋白酶原-A 聚集体。
Protein J. 2024 Aug;43(4):842-857. doi: 10.1007/s10930-024-10217-w. Epub 2024 Jul 16.
5
Myocardial edema during chemotherapy for gynecologic malignancies: A cardiac magnetic resonance T2 mapping study.妇科恶性肿瘤化疗期间的心肌水肿：一项心脏磁共振T2 图谱研究
Front Oncol. 2022 Oct 3;12:961841. doi: 10.3389/fonc.2022.961841. eCollection 2022.
6
Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy.临床表现、监测与预后：抗肿瘤治疗后心脏毒性综述
Front Cardiovasc Med. 2022 Jun 10;9:912329. doi: 10.3389/fcvm.2022.912329. eCollection 2022.
7
Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.心血管肿瘤学中的心血管影像学：超声心动图和心脏 MRI 在现代心血管肿瘤学中的作用。
Heart Fail Clin. 2022 Jul;18(3):455-478. doi: 10.1016/j.hfc.2022.02.007.
8
Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: and Molecular Docking Studies.恩格列净与阿霉素通过干扰mTOR通路和抑制钙调蛋白协同抑制三阴性乳腺癌细胞的存活：以及分子对接研究
ACS Pharmacol Transl Sci. 2020 Nov 11;3(6):1330-1338. doi: 10.1021/acsptsci.0c00144. eCollection 2020 Dec 11.
9
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer.乳腺癌治疗患者中心力衰竭的预防、检测和管理。
Curr Heart Fail Rep. 2020 Dec;17(6):397-408. doi: 10.1007/s11897-020-00486-8. Epub 2020 Sep 26.
10
Heart Failure in Relation to Anthracyclines and Other Chemotherapies.与蒽环类药物及其他化疗相关的心力衰竭
Methodist Debakey Cardiovasc J. 2019 Oct-Dec;15(4):243-249. doi: 10.14797/mdcj-15-4-243.
本文引用的文献
1
Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.基于磁共振成像的连续监测用于诊断蒽环类药物诱导的心脏毒性的早期阶段。
J Am Coll Cardiol. 2019 Feb 26;73(7):779-791. doi: 10.1016/j.jacc.2018.11.046.
2
Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.《改善心血管结局的化疗压力监测：SUCCOUR 试验》的原理与设计。
JACC Cardiovasc Imaging. 2018 Aug;11(8):1098-1105. doi: 10.1016/j.jcmg.2018.03.019. Epub 2018 Jun 13.
3
Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.心肌 T1 时间可以预测随后蒽环类药物诱导的心肌病的发展。
ESC Heart Fail. 2018 Aug;5(4):620-629. doi: 10.1002/ehf2.12277. Epub 2018 Apr 19.
4
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.卡维地洛预防化疗相关性心脏毒性：CECCY 试验。
J Am Coll Cardiol. 2018 May 22;71(20):2281-2290. doi: 10.1016/j.jacc.2018.02.049. Epub 2018 Mar 11.
5
Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).临床推荐意见：心血管磁共振 T1、T2、T2* 和细胞外容积mapping：心血管磁共振学会（SCMR）的共识声明，得到欧洲心血管影像协会（EACVI）的认可。
J Cardiovasc Magn Reson. 2017 Oct 9;19(1):75. doi: 10.1186/s12968-017-0389-8.
6
Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis.异常T2映射心血管磁共振与疑似急性心肌炎患者的不良临床结局相关。
J Cardiovasc Magn Reson. 2017 Mar 29;19(1):38. doi: 10.1186/s12968-017-0350-x.
7
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.成人癌症幸存者心功能障碍的预防和监测：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5.
8
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.辅助性乳腺癌治疗期间心脏功能障碍的预防（PRADA）：一项关于坎地沙坦和美托洛尔的2×2析因、随机、安慰剂对照、双盲临床试验。
Eur Heart J. 2016 Jun 1;37(21):1671-80. doi: 10.1093/eurheartj/ehw022. Epub 2016 Feb 21.
9
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.超声心动图心肌应变成像技术用于早期检测癌症化疗期间和化疗后患者的心脏毒性：系统评价。
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68. doi: 10.1016/j.jacc.2014.01.073. Epub 2014 Apr 2.
10
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).依那普利和卡维地洛预防恶性血液病患者化疗引起的左心室收缩功能障碍：OVERCOME 试验（依那普利和卡维地洛预防接受强化化疗治疗恶性血液病患者左心室功能障碍）。
J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072. Epub 2013 Apr 10.
Zotero 插件